Skip to main content

Japanese Patent Office Grants Claims in Alnylam's Tuschl-II Application


Alnylam Pharmaceuticals said this week that the Japanese Patent Office has granted claims in a second patent application in the so-called Tuschl II patent series.

The application, No. 2006-317758, is entitled, "RNA Interference Mediating Small RNA Molecules," according to the company.

The patent "includes 38 claims broadly covering compositions, methods, uses, and systems for double-stranded RNAs having key structural elements that are widely recognized as important for the therapeutic activity of siRNAs," Alnylam said. The Japanese Patent Office granted a related set of claims in May last year, it noted.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.